Furthermore, it is necessary to incorporate randomized clinical trials with long-term follow-up and investigate specific genetic polymorphisms of the vitamin D receptor (VDR) in people with OSCC and in OPMD, which can help develop more precise and effective chemopreventive and therapeutic strategies. This evidence concerns the gene VDR and oculopharyngeal muscular dystrophy.